Global News

First patients enrolled in REMEDEE registry

Tuesday, August 20, 2013 09:58 AM

Patient enrollment has been initiated in a post-market registry for OrbusNeich’s COMBO Dual Therapy Stent to evaluate its long-term safety and performance in routine clinical practice. The prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) Post Market Registry) will enroll 1,000 patients at nine European sites. More than 100 patients have already been enrolled.

More... »

Abbott acquires OptiMedica

Monday, August 19, 2013 02:10 PM

Abbott has acquired OptiMedica, a privately-held, Silicon Valley-based ophthalmic device company.

More... »

ACRP, ACRES collaborate to improve clinical research conduct

Monday, August 19, 2013 11:48 AM

The Association of Clinical Research Professionals (ACRP) and the Alliance for Clinical Research Excellence and Safety (ACRES) are collaborating to address challenges facing the clinical research enterprise globally and to improve medical product development and delivery worldwide.

More... »

STADA acquires Thornton & Ross

Monday, August 19, 2013 09:07 AM

Pharmaceutical company Stada Arzneimittel has purchased Thornton & Ross, a British prescription-free OTC manufacturer, after Stada and the owners had already announced exclusive contract negotiations Aug. 6.

More... »

HR+Survey Solutions CRO study finds high employee turnover rate

Friday, August 16, 2013 01:38 PM

According to the 14^th annual CRO Industry Global Compensation and Turnover Survey, conducted by HR+Survey Solutions, a compensation and research firm, CRO employees are leaving for new jobs at higher rates than their counterparts in other industries.

More... »

Assay Depot launches Pfizer virtual research platform

Friday, August 16, 2013 01:20 PM

Assay Depot, a provider of outsourced scientific services, has launched Market Exchange for Innovative Services (MXIS), a virtual outsourcing platform for Pfizer scientists. MXIS brings together research services from thousands of global vendors (aka CROs) into one secure website, enabling Pfizer scientists to communicate with any research vendor.

More... »

Arcturus Therapeutics acquires UNA patent estate from Marina Biotech

Friday, August 16, 2013 12:10 PM

Arcturus Therapeutics, which focuses on RNA interference (RNAi) technologies for the treatment of disease, has acquired the patented portfolio of Unlocked Nucleobase Analog (UNA) intellectual property from Marina Biotech. Financial terms of the UNA agreement were not disclosed.

More... »

Ligand, CURx enter global license agreement

Friday, August 16, 2013 11:20 AM

Ligand Pharmaceuticals has entered a global license agreement with CURx Pharmaceuticals for the development and commercialization of Ligand's Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate. Ligand will be eligible to receive more than $21 million in potential net milestone payments and net royalties on future sales of 6.0% to 7.5%.

More... »

Parthenon Capital acquires Bracket

Friday, August 16, 2013 10:15 AM

Bracket, a specialty services provider, has been acquired by Parthenon Capital Partners, a growth-oriented private equity firm based in Boston and San Francisco, from Express Scripts Holding Company.

More... »

Avanir, Merck announce diabetes co-promotion agreement

Thursday, August 15, 2013 12:30 PM

Avanir Pharmaceuticals has entered into an exclusive, multi-year agreement with Merck to co-promote Merck's type 2 diabetes therapies Januvia (sitagliptin) and the sitagliptin family of products in the long-term care institutional setting in the U.S.

More... »